Development and Assessment of Lipidic Nanoemulsions Containing Sodium Hyaluronate and Indomethacin

• Published in: AAPS PharmSciTech 2019-11, Vol.20 (8), p.330-330, Article 330
• Main Authors: Guermech, Ibtissem, Lassoued, Mohamed Ali, Abdelhamid, Amal, Sfar, Souad
• Format: Article
• Language: English
• Subjects: Administration, Cutaneous; Animals; Biochemistry; Biomedical and Life Sciences; Biomedicine; Biotechnology; Drug Development - methods; Emulsions; Female; Hyaluronic Acid - chemical synthesis; Indomethacin - chemical synthesis; Indomethacin - metabolism; Lipids; Male; Mice; Nanoparticles - chemistry; Nanoparticles - metabolism; Particle Size; Pharmacology/Toxicology; Pharmacy; Research Article; Skin Absorption - drug effects; Skin Absorption - physiology
• ISSN: 1530-9932; 1530-9932
• DOI: 10.1208/s12249-019-1543-4

The present work attempts to develop and optimize the formula of a lipidic nanoemulsion (NE) containing sodium hyaluronate (HNa) and indomethacin (Ind) as HNa–Ind for enhanced transdermal antiarthritic activity. NEs were prepared by the spontaneous emulsification method and characterized by Fourier-transform infrared (FTIR) spectroscopy. The composition of the optimal formulation was statistically optimized using Box–Behnken experimental design method with three independent factors and was characterized for particle size, polydispersity index, and percent transmittance. The selected formula was tested for its in vitro antioxidant activity and in vivo anti-inflammatory activity. The optimized HNa–Ind NE formula was characterized and displayed a particle size of 12.87 ± 0.032 nm, polydispersity index of 0.606 ± 0.082, and 99.4 ± 0.1 percentage of transmittance. FTIR showed no interaction between HNa and Ind as a physical mixture. In addition, the optimized HNa–Ind NE was able to preserve the antioxidant ability of the two drugs, as evidenced through a 2,2-diphenyl-1-picrylhydrazyl (DPPH) inhibition assay used to assess free radical scavenging ability. The cell viability was increased while the free radical scavenging activity was decreased (94.28% inhibition at higher concentrations compared with vitamin C as a reference with an inhibition of 100%). Moreover, the pharmacological anti-inflammatory potential of the optimized HNa–Ind NE formulation was assessed using an in vivo model. Compared with reference drugs (ibuprofen gel 5%), the remarkable activity of the optimized formulation was established using xylene-induced ear edema in mice model, in which the inflamed region reduced by 92.5% upon treatment. The optimized HNa–Ind NE formulation showed considerably higher skin permeation and drug deposition capability compared with the HNa–Ind solution. HNa–Ind NE was demonstrated to be a successful carrier with enhanced antioxidant and anti-inflammatory potential while showing better skin penetration, thus being a promising vehicle for transdermal drug delivery.